HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.

Abstract
The therapeutic efficacy of brofaromine--a new reversible and short acting MAO-A inhibitor--was evaluated in 14 inpatients with a panic disorder. In an open trial, the patients were treated with placebo during the first week and with 150 mg brofaromine per day during the following four weeks. In all patients a distinct improvement in both anxiety and depressive symptoms was observed under the active drug. Treatment outcome was the same in patients with and without a concomitant major depressive episode. No side-effects of any note were reported. Our findings suggest that the MAO-A inhibitor brofaromine is an effective drug in the treatment of anxiety disorders.
AuthorsD Garcia-Borreguero, C J Lauer, A Ozdaglar, K Wiedemann, F Holsboer, J C Krieg
JournalPharmacopsychiatry (Pharmacopsychiatry) Vol. 25 Issue 6 Pg. 261-4 (Nov 1992) ISSN: 0176-3679 [Print] Germany
PMID1494591 (Publication Type: Journal Article)
Chemical References
  • Monoamine Oxidase Inhibitors
  • Piperidines
  • brofaromine
  • Monoamine Oxidase
Topics
  • Adult
  • Agoraphobia (drug therapy, psychology)
  • Female
  • Humans
  • Male
  • Monoamine Oxidase (metabolism)
  • Monoamine Oxidase Inhibitors (adverse effects, therapeutic use)
  • Panic Disorder (drug therapy, psychology)
  • Piperidines (adverse effects, therapeutic use)
  • Psychiatric Status Rating Scales

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: